Thrombin binding aptamer, more than a simple aptamer: chemically modified derivatives and biomedical applications.

Curr Pharm Des

Institute for Research in Biomedicine, CIBER-BBN Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Edifici Helix, Barcelona, Spain.

Published: August 2012


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The thrombin binding aptamer (TBA) is a well characterized chair-like, antiparallel quadruplex structure that binds specifically to thrombin at nanomolar concentrations and therefore it has interesting anticoagulant properties. In this article we review the research involved in the development of new TBA derivatives with improved anticoagulant properties as well as the use of the TBA as a model compound for the study of quadruplex structures. Specifically, we describe the impact of modified nucleosides and non-natural backbones in the guanine tetrads or in the loops and the introduction of pendant groups at the 3' or 5'-ends. The modified oligonucleotides are shown to be excellent tools for the understanding of the molecular structure of the TBA and its folding properties. Finally, we review the use of the TBA-Thrombin recognition system for the development of analytical tools based on the TBA folding.

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161212799958387DOI Listing

Publication Analysis

Top Keywords

thrombin binding
8
binding aptamer
8
anticoagulant properties
8
tba folding
8
tba
5
aptamer simple
4
simple aptamer
4
aptamer chemically
4
chemically modified
4
modified derivatives
4

Similar Publications

3-O-sulfation of heparan sulfate (HS) is the key determinant for binding and activation of Antithrombin III (AT). This interaction is the basis of heparin treatment to prevent thrombotic events and excess coagulation. Antithrombin-binding HS (HSAT) is expressed in human tissues, but is thought to be expressed in the subendothelial space, mast cells, and follicular fluid.

View Article and Find Full Text PDF

Targeting thrombin to screen safe thrombin inhibitors from natural plants and animals is a critical direction in anticoagulant drug development. This study aimed to screen thrombin inhibitors from the nonbloodsucking leech Whitmania pigra (WP) and elucidate the mechanism of anticoagulation through a "computation-guided experimentation" strategy. A peptide library was constructed from WP hydrolysates, and virtual screening was performed using molecular docking and dynamics simulations.

View Article and Find Full Text PDF

Immune thrombocytopenia (ITP) is one of the most common causes of decreased platelet count. Bleeding is the main clinical symptom of ITP; although its severity correlates with the depth of thrombocytopenia, it may also depend on changes in the functional activity of platelets. In this study we have compared platelet functional activity in healthy volunteers (HV) and in ITP patients, as well as in groups of ITP patients with different levels of bleeding.

View Article and Find Full Text PDF

Discovery of Pyrazole-3-Carboxylic Acid Derivatives as Dengue Virus Protease Inhibitors with Antiviral Activity.

ACS Med Chem Lett

August 2025

Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology IPMB, Heidelberg University, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany.

We present the discovery of pyrazole-3-carboxylic acid derivatives as novel dengue virus (DENV) NS2B-NS3 protease inhibitors. The discovery was triggered by omission of the phenylglycine scaffold of previous lead structures. We established a robust, regioselective synthetic route toward pyrazole-3-carboxylic acid derivatives.

View Article and Find Full Text PDF

Covalent Organic Framework-Based Porous Anticoagulant Materials for Extracorporeal Blood Circulation.

Adv Healthc Mater

August 2025

Key Laboratory of Cluster Science, Ministry of Education, Beijing Key Laboratory of Photoelectronic/Electrophotonic Conversion Materials, Advanced Research Institute of Multidisciplinary Science, Frontiers Science Center for High Energy Material, Advanced Technology Research Institute (Jinan), Schoo

Preventing coagulation during extracorporeal blood circulation is critical for clinical treatments. Developing anticoagulant materials for key components can reduce reliance on systemic anticoagulants and improve safety. However, such materials often show limited efficacy due to inefficient interactions with pro/anti-coagulation components, resulting from random active site distribution and orientation.

View Article and Find Full Text PDF